Production, safety and antitumor efficacy of recombinant Oncofetal Antigen/immature laminin receptor protein

Biomaterials

Volumn 30, Issue 17, 2009, Pages 3091-3099

  Barsoum, Adel L ^a   Liu, Bainan ^a   Rohrer, James W ^a   Coggin Jr , Joseph H ^a   Tucker, J Allan ^a   Pannell, Lewis K ^b   Schwarzenberger, Paul O ^a  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^b Department of Medicine USA College of Medicine   (United States)

Author keywords

Cancer vaccine; Laminin receptor precursor; Oncofetal Antigen immature laminin receptor protein; Recombinant protein

Indexed keywords

ANION EXCHANGES; ANTI-TUMOR ACTIVITIES; ANTI-TUMOR EFFICACIES; BREAST CANCERS; CANCER VACCINE; DENDRITIC CELLS; GEL FILTRATIONS; HIGH YIELDS; HIS TAGS; HOST CELL PROTEINS; HUMAN CANCERS; IMMOBILIZED METALS; INCLUSION BODIES; LAMININ RECEPTOR PRECURSOR; MURINE MODELS; ONCOFETAL ANTIGEN/IMMATURE LAMININ RECEPTOR PROTEIN; RECOMBINANT PROTEIN; SOLID TUMORS; TUMOR ANTIGENS;

ANTIGENS; CELL CULTURE; CHLORINE COMPOUNDS; CHROMATOGRAPHIC ANALYSIS; COLUMN CHROMATOGRAPHY; DENDRIMERS; ESCHERICHIA COLI; GELATION; MAMMALS; METAL REFINING; PROTEINS; PURIFICATION; TUMORS;

VACCINES;

CELL PROTEIN; COMPLEMENTARY DNA; ENDOTOXIN; GUANIDINE; LAMININ RECEPTOR; LIPOSOME; METAL; POLYHISTIDINE TAG; RECOMBINANT ONCOFETAL ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANION EXCHANGE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIUM CULTURE; BLOOD CELL COUNT; BREAST CANCER; CANCER PATIENT; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; ENZYME ISOLATION; ESCHERICHIA COLI; FEMALE; FIBROSARCOMA; FOOD AND DRUG ADMINISTRATION; GEL FILTRATION; HOST CELL; HUMAN; IMMOBILIZATION; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN PURIFICATION; SOLID TUMOR; SOLUBILITY; TUMOR REJECTION;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; CLONING, MOLECULAR; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; FEMALE; FIBROSARCOMA; GUANIDINE; HISTIDINE; HUMANS; INCLUSION BODIES; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; MOLECULAR WEIGHT; PLASMIDS; QUALITY CONTROL; RECEPTORS, LAMININ; RECOMBINANT PROTEINS; RIBOSOMAL PROTEINS; SOLUBILITY; TRANSFORMATION, BACTERIAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; MAMMALIA; MURINAE; MUS;

EID: 64249130095     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2009.02.022     Document Type: Article

References (40)

1. Coggin Jr. J.H., Barsoum A.L., and Rohrer J.W. Tumors express both unique TSTA and crossprotective 44 kDa oncofetal antigen. Immunol Today 19 (1998) 405-408
2. Coggin Jr. J.H., Rohrer S.D., Hester R.D., Barsoum A.L., Rashid H.U., and Gussack G.S. 44 Kd oncofetal transplantation antigen in rodent and human fetal cells: implications of recrudescence in human and rodent cancers. Arch Otolaryngol Head Neck Surg 119 (1993) 1257-1266
3. Payne Jr. W.J., and Coggin Jr. J.H. Mouse monoclonal antibody to embryonic antigen: development, cross-reactivity with rodent and human tumors, and preliminary polypeptide characterization. J Natl Cancer Inst 75 (1985) 527-544
4. Gussack G.S., Rohrer S.D., Hester R.B., Liu P.I., and Coggin Jr. J.H. Human squamous cell carcinoma lines express oncofetal 44 kD polypeptide defined by monoclonal antibody to mouse fetus. Cancer 62 (1988) 283-290
5. Rohrer J.W., Barsoum A.L., and Coggin Jr. J.H. The development of a new universal tumor rejection antigen expressed on human and rodent cancers for vaccination, prevention of cancer, and anti-tumor therapy. Mod Asp Immunobiol 1 (2001) 191-195
6. Coggin Jr. J.H., Barsoum A.L., and Rohrer J.W. 37 kiloDalton oncofetal antigen protein and immature laminin receptor protein are identical, universal T-cell inducing immunogens on primary rodent and human cancers. Anticancer Res 19 (1999) 5535-5542
7. Barsky S.H., Rao C.N., Williams J.E., and Liotta L.A. Laminin molecular domains which alter metastasis in a murine model. J Clin Invest 74 (1984) 843-848
8. Barsoum A.L., Rohrer J.W., and Coggin Jr. J.H. 37 kDa oncofetal antigen is an autoimmunogenic homologue of the 37 kDa laminin receptor precursor. Cell Mol Biol Lett 5 (2000) 207-230
9. Yow H.K., Wong J.M., Chen H.S., Lee C.G., Davis S., Steele Jr. G.D., et al. Increased mRNA expression of a laminin-binding protein in human colon carcinoma: complete sequence of a full-length cDNA encoding the protein. Proc Natl Acad Sci U S A 85 (1988) 6394-6398
10. Rao C.N., Castronovo V., Schmitt M.C., Wewer U.M., Claysmith A.P., Liotta L.A., et al. Evidence for a precursor of the high-affinity metastasis-associated murine laminin receptor. Biochemistry 28 (1989) 7476-7486
11. Landowski T.H., Dratz E.A., and Starkey J.R. Studies of the structure of the metastasis-associated 67 kDa laminin binding protein: fatty acid acylation and evidence supporting dimerization of the 32 kDa gene product to form the mature protein. Biochemistry 34 (1995) 11276-11287
12. Butò S., Tagliabue E., Ardini E., Magnifico A., Ghirelli C., van den Brûle F., et al. Formation of the 67-kDa laminin receptor by acylation of the precursor. J Cell Biochem 69 (1998) 244-251
13. Demeter L.M., Stoler M.H., Sobel M.E., Broker T.R., and Chow L.T. Expression of high-affinity laminin receptor mRNA correlates with cell proliferation rather than invasion in human papillomavirus-associated cervical neoplasms. Cancer Res 52 (1992) 1561-1567
14. Sobel M.E. Differential expression of the 67 kDa laminin receptor in cancer. Semin Cancer Biol 4 (1993) 311-317
15. Ménard S., Castronovo V., Tagliabue E., and Sobel M.E. New insights into the metastasis-associated 67 kD laminin receptor. J Cell Biochem 67 (1997) 155-165
16. Friedrichs B., Siegel S., Kloess M., Barsoum A., Coggin Jr. J., Rohrer J., et al. Humoral immune responses against the immature laminin receptor protein show prognostic significance in patients with chronic lymphocytic leukemia. J Immunol 180 (2008) 6374-6384
17. Rohrer J.W., Barsoum A.L., Dyess D.L., Tucker J.A., and Coggin Jr. J.H. Human breast carcinoma patients develop clonable oncofetal antigen-specific effector and regulatory T lymphocytes. J Immunol 162 (1999) 6880-6892
18. Rohrer J.W., Rohrer S.D., Barsoum A., and Coggin Jr. J.H. Differential recognition of murine tumor-associated oncofetal transplantation antigen and individually specific tumor-transplantation antigens by syngeneic cloned Balb/c and Rfm mouse T-cells. J Immunol 152 (1994) 754-764
19. Rohrer J.W., Culpepper C., Barsoum A.L., and Coggin Jr. J.H. Characterization of Rfm mouse T-lymphocyte anti-oncofetal antigen immunity in apparent tumor-free, long-term survivors of sublethal X-irradiation by limiting dilution T-lymphocyte cloning. J Immunol 154 (1995) 2266-2280
20. Siegel S., Wagner A., Kabelitz D., Marget M., Coggin Jr. J., Barsoum A., et al. Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies. Blood 102 (2003) 4416-4423
21. *0201-presented T cell epitopes derived from the oncofetal antigen-immature laminin receptor protein in patients with hematological malignancies. J Immunol 176 (2006) 6935-6944
22. Rohrer J.W., Barsoum A.L., and Coggin Jr. J.H. Identification of oncofetal antigen/immature laminin receptor protein epitopes that activate BALB/c mouse OFA/iLRP-specific effector and regulatory T cell clones. J Immunol 176 (2006) 2844-2856
23. Höltl L., Zelle-Rieser C., Gander H., Papesh C., Ramoner R., Bartsch G., et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 8 (2002) 3369-3376
24. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
25. Towbin H., Staehelin T., and Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 76 (1979) 4350-4354
26. Liu S., Tobias R., McClure S., Styba G., Shi Q., and Jackowski G. Removal of endotoxin from recombinant protein preparations. Clin Biochem 30 (1997) 455-463
27. Satoh K., Narumi K., Sakai T., Abe T., Kikuchi T., Matsushima K., et al. Cloning of 67-kDa laminin receptor cDNA and gene expression in normal and malignant cell lines of the human lung. Cancer Lett 62 (1992) 199-203
28. Schmidt M., Viaplana E., Hoffmann F., Marten S., Villaverde A., and Rinas U. Secretion-dependent proteolysis of heterologous protein by recombinant Escherichia coli is connected to an increased activity of the energy-generating dissimilatory pathway. Biotechnol Bioeng 66 (1999) 61-67
29. Murphy R., Green S., Ritter G., Cohen L., Ryan D., Woods W., et al. Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions. Prep Biochem Biotechnol 35 (2005) 119-134
30. Osterloh A., Meier-Stiegen F., Veit A., Fleischer B., von Bonin A., and Breloer M. Lipopolysaccharide-free heat shock protein 60 activates T cells. J Biol Chem 279 (2004) 47906-47911
31. Fong L., Brockstedt D., Benike C., Wu L., and Engleman E.G. Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol 166 (2001) 4254-4259
32. Vangala A., Kirby D., Rosenkrands I., Agger E.M., Andersen P., and Perrie Y. A comparative study of cationic liposome and niosome-based adjuvant systems for protein subunit vaccines: characterisation, environmental scanning electron microscopy and immunisation studies in mice. J Pharm Pharmacol 58 (2006) 787-799
33. Chikh G., and Schutze-Redelmeier M.P. Liposomal delivery of CTL epitopes to dendritic cells. Biosci Rep 22 (2002) 339-353
34. Guan H.H., Budzynski W., Koganty R.R., Krantz M.J., Reddish M.A., Rogers J.A., et al. Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses. Bioconjug Chem 9 (1998) 451-458
35. Xiang S.D., Scalzo-Inguanti K., Minigo G., Park A., Hardy C.L., and Plebanski M. Promising particle-based vaccines in cancer therapy. Expert Rev Vaccines 7 (2008) 1103-1119
36. Disis M.L., Schiffman K., Guthrie K., Salazar L.G., Knutson K.L., Goodell V., et al. Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein-based vaccine. J Clin Oncol 22 (2004) 1916-1925
37. Marchand M., Punt C.J., Aamdal S., Escudier B., Kruit W.H., Keilholz U., et al. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer 39 (2003) 70-77
38. Wada H., Sato E., Uenaka A., Isobe M., Kawabata R., Nakamura Y., et al. Analysis of peripheral and local anti-tumor immune response in esophageal cancer patients after NY-ESO-1 protein vaccination. Int J Cancer 123 (2008) 2362-2369
39. Kawabata R., Wada H., Isobe M., Saika T., Sato S., Uenaka A., et al. Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients. Int J Cancer 120 (2007) 2178-2184
40. Coggin Jr. J.H., Barsoum A.L., Rohrer J.W., Thurnher M., and Zeis M. Contemporary definitions of tumor specific antigens, immunogens and markers as related to the adaptive responses of the cancer-bearing host. Anticancer Res 25 (2005) 2345-2355